Assessing Barticinib role in mitigate autoimmune response and preserve insulin-producing beta cells in patients with newly diagnosed type 1 diabetes
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 19th, 2024
|
Individuals afflicted by Type 1 diabetes necessitate insulin supplementation due to their pancreas' incapacity to generate adequate insulin. Studies indicate that safeguarding the residual insulin-producing beta cells can mitigate the severity of the disease. Baricitinib, a JAK inhibitor, has the potential to impede the destructive behavior of autoreactive CD8 T-cells. Consequently, a study aimed to evaluate Baricitinib's capability in impeding autoreactive responses and conserving insulin-producing beta cells.
The phase 2 clinical trial involved 91 individuals aged 10 to 30 years, who were recently diagnosed with type 1 diabetes within 100 days before study enrollment. Blood tests confirmed the presence of at least one autoreactive antibody type and a C-peptide level exceeding 0.3 nmol per liter. The participants had an average body mass index of approximately 18.5 and a median glycated hemoglobin level of around 7%. Randomly allocated, they received either 4 mg of oral Baricitinib daily or a placebo. Following 48 weeks of treatment, the study revealed that the median mixed-meal-stimulated C-peptide level reached 0.65 nmol per liter per minute, notably higher than the 0.43 nmol per liter per minute observed in the placebo group. This outcome suggested the effectiveness of Baricitinib in preserving beta cells' insulin production capacity. Consequently, individuals in the Baricitinib group required less insulin supplementation, with a daily insulin dose of 0.41 U per kilogram of body weight, compared to 0.52 U in the control group. The sustained insulin production contributed to more stable blood glucose levels among those treated with Baricitinib.
The phase 2 clinical trial involved 91 individuals aged 10 to 30 years, who were recently diagnosed with type 1 diabetes within 100 days before study enrollment. Blood tests confirmed the presence of at least one autoreactive antibody type and a C-peptide level exceeding 0.3 nmol per liter. The participants had an average body mass index of approximately 18.5 and a median glycated hemoglobin level of around 7%. Randomly allocated, they received either 4 mg of oral Baricitinib daily or a placebo. Following 48 weeks of treatment, the study revealed that the median mixed-meal-stimulated C-peptide level reached 0.65 nmol per liter per minute, notably higher than the 0.43 nmol per liter per minute observed in the placebo group. This outcome suggested the effectiveness of Baricitinib in preserving beta cells' insulin production capacity. Consequently, individuals in the Baricitinib group required less insulin supplementation, with a daily insulin dose of 0.41 U per kilogram of body weight, compared to 0.52 U in the control group. The sustained insulin production contributed to more stable blood glucose levels among those treated with Baricitinib.